HTR1D
5-hydroxytryptamine receptor 1D
As of the edition of 20 October 2026, HTR1D (5-hydroxytryptamine receptor 1D, UniProt P28221) has 14 drugs tested at it and 25 companies on the list, 1 on route A and 8 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P28221
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Nervous system; Inherited and neonatal; Mental health; Lungs and airways; Nutrition and metabolism; Cancer; Chemically induced; Heart and blood vessels
- Registered trials of its drugs
- 179
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 10 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sumatriptan | Marketed | Phase 4 | none listed |
| Fenfluramine | Marketed | Phase 4 | Ends 2036 |
| Rizatriptan | Marketed | Phase 4 | none listed |
| Zolmitriptan | Marketed | Phase 4 | none listed |
| Dihydroergotamine | Marketed | Phase 4 | none listed |
| Eletriptan | Marketed | Phase 4 | none listed |
| Almotriptan | Marketed | Phase 4 | none listed |
| NP-101 | Stopped | Phase 3 | none listed |
| Frovatriptan | Marketed | Phase 4 | none listed |
| Naratriptan | Marketed | Phase 3 | none listed |
| GSK163090 | Went quiet | Phase 1 | none listed |
| DFN-02 | Went quiet | Phase 3 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 8 |
| Engaged | 2 |
| Undetermined | 14 |
| Total on the list | 25 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| UCB | Route B |
| Johnson & Johnson | Route B |
The other 22 companies at HTR1D
In the product25 companies in all; 22 are not named here, and no score is.
See the 25 companies at HTR1D, ranked, with the facts behind eachRequest access. Nothing is shown until you do.